[Retrospective investigation on the cases treated with liposomal XXXX ].

@entity1 @entity295 @entity11930 @entity2379 @entity326 @entity2348 @entity1483 @entity281 @entity1398 @entity972 @entity1011 @entity204 @entity166 @entity19095
We have retrospectively investigated clinical profile, efficacy, and safety in 41 @entity1 who were treated with liposomal @entity2379 ( @entity19095 ) in Aichi Medical University Hospital between January 2008 and June 2009. It turned out that @entity19095 was used for severe @entity166 and 31.7% cases discontinued @entity19095 therapy because of @entity204 . @entity19095 was administered as the second-line therapy in 56.1% (23/41), and was not effective in 48.8% (20/41). @entity19095 was administered as the first-line therapy in 43.9% (18/41); (1) 1 for @entity281 , (2) 7 for severe @entity295 or @entity326 , (3) 2 for the case which cannot remove medical device and might have biofilm formation, (4) 6 for the induction of step-down therapy concept, (5) 2 for febrile @entity1398 @entity1 who have needed aggressive empiric therapy. There was no significant difference in serum @entity972 level (p = 0.10) and serum @entity1011 level (p = 0.05) between pretreatment and posttreatment with @entity19095 . The serum @entity1011 level before initial treatment with @entity19095 was 1.31 +/- 1.30 mg/dL. The @entity1 for 7.3% (3 cases) had dialyzed before initial treatment with @entity19095 , however, there was no case who need dialysis after administration of @entity19095 . As for the highest @entity1011 level in @entity19095 administered cases, 29.3% (12/41) and 24.4% (10/41) were normal to abnormal, and abnormal to abnormal, respectively. This is the first investigational report when the serum @entity1011 level before initial administration of @entity11930 had been abnormal. The other antimicrobial agents, which might have influenced renal function, were administered to 51.2% cases (21/41). That means the cases administered @entity19095 might have other @entity2348 . As for the serum @entity1011 level, we observed the changing cases and the cases which did not cause the change at all regardless of the administering period of @entity11930 . The serum @entity972 level before initial administration of @entity19095 was 4.1 +/- 0.8 mEq/L, concomitant use of @entity1483 etc. was 31.7% (13/41), the lowest serum @entity972 level was 3.4 +/- 0.9 (1.9-6.2)mEq/L in during using @entity19095 , the serum @entity972 was 34.1% (14/41) in replenish @entity972 during administration of @entity19095 , and the total replenished @entity972 was 131.25 mEq. We did not observe the case who had died because of the low @entity972 . Since @entity19095 was the only fungicidal drug, when we use @entity19095 for the serious @entity166 to make the best use of the characteristic, we have to pay attention to the concomitant medication, renal function and the serum @entity972 level.
